Publications de 1994 à 1996

Publications scientifiques 1996

1. Cell proliferation in chemical hepatocarcinogenesis. In vivo analysis using retroviral mediated gene transfer Lab.
Bralet MP, Calise D, Bréchot C and Ferry N. (1996)
Invest. 74: 871-881.

2. Efficient transfer of regulated genes in adipocytes and hepatoma cells by the combination of liposomes and replication defective adenovirus.
Meunier-Durmort C, Ferry N, Hainque B, Delattre J and Forest C. (1996)
Eur. J. Biochem. 237: 660-667.

3. In vivo retroviral mediated transfer of a marker gene in ornithine transcarbamylase deficient spf-ash mice.
Podevin G, Ferry N, Calise D and Révillon Y. (1996)
J. Pediatr. Surg. 31: 1516-1519.

4. In vitro and in vivo hepatoma cell specific expression of a gene transferred with an adenoviral vector.
Arbuthnot P, Bralet MP, Le Jossic C, Dedieu JF, Perricaudet M, Brechot C and Ferry N.
Human Gene Ther. 7: 1503-1514.(1996)

Publications scientifiques 1995

1. Retroviral-mediated gene transfer corrects very-long-chain fatty acid metabolism in adrenoleukodystrophy fibroblasts.
Cartier N., Lopez J., Moullier P., Rocchiccioli F., Rolland MO., Jorge P., Mosser J., Mandel JL., Bougneres PF., Danos O., et al.
Proc Natl Acad Sci U S A . 1995, 92:1674-8.

2. Sustained delivery of erythropoietin in mice by genetically modified skin fibroblasts.
Naffakh N., Henri A., Villeval JL., Rouyer-Fessard P., Moullier P., Blumenfeld N., Danos O., Vainchenker W., Heard JM., Beuzard Y.
Proc Natl Acad Sci U S A . 1995, 92:3194-8.

3. Long-term delivery of a lysosomal enzyme by genetically modified fibroblasts: pre-clinical evaluation of efficacy and safety in dogs.
Moullier, P., Bohl, D., Cardoso, J., Heard, J.M. and Danos, O.
Nature. Med. 1:353-357.

4. In vivo delivery of human a-L-iduronidase in mice implanted with neo-organs.
Salvetti, A., Moullier, P., Cornet, V., Brooks, D., Hopwood, J.J., Danos, O. and Heard, J.M.
Hum. Gene Ther. 1995, 6: 1153-1159.

5. Gene therapy of lysosomal storage disorders.
A.Salvetti , J.M. Heard, O.Danos.
British Med. Bull. 1995. 51: 106-122.

6. Functional retroviral vector for gene therapy of xeroderma pigmentosum group D patients.
M. Carreau, X. Quilliet, E. Eveno, A. Salvetti, O. Danos, J.M. Heard, M. Mezzina, A. Sarasin. .
Hum. Gene Ther. 1995. 6:1307-1315.

7. Correction of fumarylacetoacetate hydrolase deficiency (type I tyrosinemia) in cultured human fibroblasts by retroviral-mediated gene transfer.
Phaneuf D, Hadchouel M, Tanguay R.M, Bréchot C and Ferry N
Biochem. Biophys. Res. Commun. 1995 Mar 28 ; 208(3) : 957-963.

8. Hepatoma cell specific expression of a retrovirally transferred gene is achieved by alpha-fetoprotein but not insulinlike growth factor II regulatory sequences.
Arbuthnot P, Bralet M.P, Thomassin H, Danan J.L, Bréchot C and Ferry N
Hepatology. 1995 Dec ;22(6) : 1788-1796.

Publications scientifiques 1994

1. Association of 1078 del T cystic fibrosis mutation with severe disease.
Moullier P., Jehanne M., Audrezet MP., Mercier B., Verlingue C., Quere I., Guillermit H., Raguenes O., Storni V., Rault G., et al.
J Med Genet . 1994, 31:159-61.

2. Adenoviral-mediated gene transfer to renal tubular cells in vivo.
Moullier P., Friedlander G., Calise D., Ronco P., Perricaudet M., Ferry N.
Kidney Int. 1994, 45:1220-5.

3. Cell lineage study in the liver using retroviral mediated gene transfer.
Bralet MP, Branchereau S, Brechot C and Ferry N (1994)
Amer. J. Pathol. 1994 May ;144(05): 896-905.

4. Factors influencing retroviral mediated gene transfer into hepatocytes in vivo.
Branchereau S, Calise D and Ferry N. (1994)
Human Gene Ther. 1994 jul ; 5(7) : 803-808.

Mis à jour le 29 mars 2018.